LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.27 -0.93

Buy Sell

Overview

Share price change

24h

Current

Min

4.23

Max

4.37

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+224.07% upside

Market Stats
By TradingEconomics
Market Cap	-14M 240M
Previous open	5.2
Previous close	4.27

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 gru 2025, 22:13 UTC

Earnings

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 gru 2025, 21:40 UTC

Earnings

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 gru 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 gru 2025, 16:57 UTC

Major Market Movers

Clear Secure Rises on Medicare Identity Verification Contract

9 gru 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 gru 2025, 23:46 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 gru 2025, 23:45 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 gru 2025, 23:44 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 gru 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 gru 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 gru 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 gru 2025, 22:42 UTC

Earnings

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 gru 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 gru 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 gru 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9 gru 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 gru 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 gru 2025, 20:26 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 gru 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 gru 2025, 19:52 UTC

Earnings

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 gru 2025, 19:17 UTC

Earnings

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 gru 2025, 17:11 UTC

Earnings

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

224.07% upside

12 Months Forecast

Average 14 USD 224.07%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.